Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Notable: Berobenatide · Urine Leakage and With Obesity or Overweight (VESPER-SUI) Recruitment opened
- Notable: 177Lu-NYM032 Injection · Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Recruitment opened
- Notable: Zigakibart + Atrasentan · Primary IgA Nephropathy Recruitment opened
- Notable: Efgartigimod · Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY) Recruitment opened
- Notable: Single-agent Therapy of BR113 for Injection · Advanced Solid Tumors Recruitment opened
- Notable: ABI-6250 · Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function Recruitment opened
- Notable: Distribution,Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 · IRM Recruitment opened
- Notable: Nutritional Supplementation on Actinic Purpura: A Pilot Study Trial status changed: Suspended → Withdrawn
- Notable: GRACE-DE · Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study) Recruitment opened
- Notable: BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4 Recruitment opened
- Notable: Pediatric Sleep Study Recruitment opened
- Notable: IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer Recruitment opened
- Notable: Comparative Study of Percutaneous Pulsed Field Ablation Guided by Ultrasound Alone Versus Fluoroscopy · Atrial Fibrillation Recruitment opened
- Notable: Metabolic Changes Associated With Weight Gain After Treatment of Achalasia Recruitment opened
- Notable: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial Recruitment opened
- Notable: Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery Recruitment opened
- Notable: Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery Recruitment opened
- Notable: Baricitinib · Cardiac Sarcoidosis Recruitment opened
- Notable: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) Recruitment opened
- Notable: Tiprelestat Versus Placebo When Added to Standard of Care · Pulmonary Arterial Hypertension (PAH) Enrolling by invitation only
- Notable: Vaccine (STEMVAC) for Improving Survival · Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden Recruitment opened
- Notable: Hyaluronidase Injections for Sclerodactyly · Scleroderma Recruitment opened
- Notable: Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery Recruitment opened
- Notable: Use of A Complex Gut Bacterial Consortium (MITI 001) · Irritable Bowel Syndrome With Diarrhea Recruitment opened
- Notable: Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for Alcohol Use Disorder Following Sexual Assault in College Women Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates